{"id":"rebamipide-and-omeprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rebamipide is a mucoprotective agent that enhances gastric mucus secretion, increases bicarbonate production, and promotes mucosal blood flow to protect the stomach lining. Omeprazole is a proton pump inhibitor that suppresses gastric acid production by blocking H+/K+-ATPase in parietal cells. Together, this combination provides both acid reduction and direct mucosal protection for enhanced gastroprotection.","oneSentence":"Rebamipide protects and promotes gastric mucosa healing while omeprazole reduces gastric acid secretion by inhibiting the proton pump.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:24.206Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric ulcer disease"},{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Gastric mucosal protection in peptic ulcer disease"}]},"trialDetails":[{"nctId":"NCT02134405","phase":"PHASE4","title":"Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2014-08","conditions":"Dyspepsia","enrollment":200},{"nctId":"NCT00272467","phase":"PHASE4","title":"Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy","status":"COMPLETED","sponsor":"Korea Otsuka International Asia Arab","startDate":"2005-07","conditions":"Stomach Ulcer","enrollment":132},{"nctId":"NCT01150162","phase":"PHASE3","title":"Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation","status":"COMPLETED","sponsor":"Otsuka Pakistan Limited","startDate":"2010-10","conditions":"Gastric Ulcer","enrollment":129},{"nctId":"NCT00641004","phase":"PHASE4","title":"Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical, Inc., Philippines","startDate":"2008-04","conditions":"NSAID Induced Gastropathy","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mucosta","Omeprazole"],"phase":"phase_3","status":"active","brandName":"Rebamipide and Omeprazole","genericName":"Rebamipide and Omeprazole","companyName":"Otsuka Pakistan Limited","companyId":"otsuka-pakistan-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rebamipide protects and promotes gastric mucosa healing while omeprazole reduces gastric acid secretion by inhibiting the proton pump. Used for Gastric ulcer disease, Gastroesophageal reflux disease (GERD), Gastric mucosal protection in peptic ulcer disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}